Nice find SL, The Journal Transcript article from yesterday states:
We think the final run into year-end might be the best of all. Our goal is to help you find that “GI Joe with the Kung Fu Grip” for Christmas this year. And we see ENTB as an incredible opportunity with the potential to get the job done.
Would be great to see a year end run. The low float as they pointed out could be a game changer when it runs.
In the last two Regen Biopharma PR's they referenced Zander(ENTB) as follows:
12/7/16 PR
Regen BioPharma, Inc. is developing small molecule inhibitors and activators of NR2F6. Inhibitors (which inhibit the expression of NR2F6) are expected to be useful in the treatment of various cancers and activators (which activate the expression of NR2F6) in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis
Regen is also party to an agreement whereby Zander Therapeutics, Inc. has been granted by Regen an exclusive worldwide right and license for the development and commercialization of NR2F6 intellectual property controlled by Regen for non-human veterinary therapeutic use. Controlling NR2F6 in dogs and cats may be effective in treating diseases such cancer and arthritis at the veterinary level.
12/15/16 PR
Remarkable clinical results have been obtained by numerous investigators utilizing CAR T cells in the treatment of leukemias and lymphomas[1]. Unfortunately, results for solid tumors have been limited[2]. This is thought to occur because solid tumors produce numerous immune-suppressive factors that coax the cells that surround the tumor to protect the tumor against the immune response. By utilizing NR2F6-silencing methods, Regen believes it has developed a new method of augmenting the cells that surround the tumor to allow for immune destruction of the tumor to occur.
Further, Dr. Koos noted "We believe there is a spillover effect with this new approach that will be valuable to our licensee for veterinary applications, Zander Therapeutics Inc. (a wholly owned subsidiary of Entest BioMedical Inc., PINKS: ENTB)."
